Equitable Holdings Inc. Takes $1.56 Million Position in Repligen Corporation $RGEN

Key Points

• Equitable Holdings acquired 11,404 Repligen shares worth approximately $1.56 million during the second quarter. Institutional investors and hedge funds collectively own 97.64% of Repligen’s stock.
• Analyst sentiment remains positive: Repligen has an average “Buy” rating and a consensus price target of $166.43, with recent upgrades from Benchmark and JPMorgan.
• Repligen exceeded quarterly expectations, reporting $0.54 EPS versus the $0.45 consensus and $204.13 million in revenue, up 11.9% year over year. Shares opened at $176.27, near their 52-week high of $188.73.

Equitable Holdings Inc. bought a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,404 shares of the biotechnology company's stock, valued at approximately $1,556,000.

Several other institutional investors have also modified their holdings of RGEN. Measured Wealth Private Client Group LLC acquired a new stake in Repligen during the 3rd quarter valued at approximately $29,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen in the 4th quarter valued at approximately $36,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Repligen during the 2nd quarter valued at approximately $52,000. Farther Finance Advisors LLC boosted its stake in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock valued at $55,000 after buying an additional 128 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its position in shares of Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company's stock worth $62,000 after buying an additional 104 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of research analyst reports. Benchmark upgraded shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a research note on Tuesday, July 7th. HSBC decreased their price objective on shares of Repligen from $170.00 to $150.00 and set a "buy" rating for the company in a report on Wednesday, June 3rd. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada began coverage on shares of Repligen in a research report on Thursday, May 14th. They set an "outperform" rating and a $160.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $166.43.

Insiders Place Their Bets

In other Repligen news, CFO Jason K. Garland sold 733 shares of the firm's stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.60% of the stock is owned by corporate insiders.

Repligen Stock Down 3.2%

NASDAQ:RGEN opened at $176.27 on Friday. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock has a 50 day moving average of $151.99 and a 200-day moving average of $133.09. The firm has a market capitalization of $9.95 billion, a PE ratio of 241.47, a price-to-earnings-growth ratio of 3.32 and a beta of 1.03. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $188.73.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same quarter last year, the business posted $0.26 EPS. The business's revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts predict that Repligen Corporation will post 2.06 EPS for the current year.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source